Related Experiment Video
Updated: Jul 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Cerebral Amyloid Angiopathy and Atrial Fibrillation: An up to Date Case Report
Umberto Battistin1, Noora AlQassim1, Yusuf Hallak1
1College of Medicine, Mohammad Bin Rashid University of Medicine and Health Sciences, Dubai, UAE.
Insights
Managing patients with concurrent Cerebral Amyloid Angiopathy (CAA) and atrial fibrillation presents a challenge. Balancing anticoagulation for atrial fibrillation against hemorrhage risk from CAA requires careful consideration and multidisciplinary input.
Area of Science:
- Neurology
- Cardiology
- Geriatrics
Background:
- Concurrent Cerebral Amyloid Angiopathy (CAA) and atrial fibrillation (AF) pose a growing clinical challenge, particularly in aging populations.
- Managing these conditions requires balancing the risk of ischemic stroke from AF against the risk of intracerebral hemorrhage from CAA.
Observation:
- A case report details a 67-year-old woman with AF on rivaroxaban experiencing transient neurological deficits.
- These deficits were diagnosed as amyloid spells, indicating concomitant CAA.
Findings:
- The case highlights the dilemma of anticoagulation in patients with both AF and CAA.
- Current literature lacks a clear consensus on optimal anticoagulation management for such patients.
Implications:
- Optimal management necessitates a multidisciplinary team approach.
- Further research is needed to establish evidence-based guidelines for anticoagulation in patients with concurrent AF and CAA.
Abstract:
Concurrent Cerebral Amyloid Angiopathy (CAA) and Atrial Fibrillation are becoming an increasingly common dilemma in clinical practice due to the aging population and the comorbidities associated with it. In such patients, the physician must appreciate and strike the difficult balance between the risk of ischemic strokes from atrial fibrillation on one hand, and that of intracerebral hemorrhage from coexisting CAA on the other. Anticoagulation is necessary for the former but potentially deleterious for the latter. In this case report, we present the case of a 67-year-old woman with a long history of atrial fibrillation on rivaroxaban who recently began to experience recurrent transient neurological deficits that were later diagnosed as amyloid spells related to concomitant CAA. While there is no clear-cut consensus in published literature on how to best manage these patients regarding the use of anticoagulation, it is recommended to involve a multidisciplinary team for optimal management of these patients.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Hemorrhagic Stroke l: Introduction
Cerebral Edema l: Introduction
Cerebral Edema ll: Pathophysiology
Dementia l: Introduction